Although statin use post-endovascular aortic repair has shown lower long-term mortality without predisposition to muscle wasting based on successive SMA measurements [29], statin-induced myopathy shares some proposed mechanisms with myopenia and sarcopenia in HF, such as mitochondrial dysfunction [30] and ubiquitin-proteasome system upregulation [31, 32]. Here, SMN1 is linked to myopathy.